曲妥珠单抗-德鲁替康：一种在乳腺癌中展现其命运的抗体药物偶联物。
Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer.
机构信息
University of Pennsylvania, Department of Medicine, Division of Hematology and Oncology, Philadelphia, PA 19104, USA.
University of Pennsylvania, Department of Medicine, Division of Hematology and Oncology, Philadelphia, PA 19104, USA.
出版信息
Cell Rep Med. 2022 Jun 21;3(6):100668. doi: 10.1016/j.xcrm.2022.100668.
Abstract
In DESTINY-Breast 03, Trastuzumab Deruxtecan, a HER2-specific antibody-drug conjugate, proved superior to T-DM1 in patients with HER2+ metastatic breast cancer progressing on taxane and trastuzumab. This study supported its recent approval as second-line therapy in HER2+ metastatic breast cancer.
摘要
在 DESTINY-Breast 03 研究中，曲妥珠单抗-美坦新偶联物（一种 HER2 特异性抗体药物偶联物）在接受过紫杉烷和曲妥珠单抗治疗后疾病进展的 HER2+转移性乳腺癌患者中优于 T-DM1。该研究支持其最近被批准用于 HER2+转移性乳腺癌的二线治疗。
相似文献
1
Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer.曲妥珠单抗-德鲁替康：一种在乳腺癌中展现其命运的抗体药物偶联物。
Cell Rep Med. 2022 Jun 21;3(6):100668. doi: 10.1016/j.xcrm.2022.100668.
2
T-DXd: New Standard for HER2-Low Breast Cancer.T-DXd：HER2 低表达乳腺癌的新标准。
Cancer Discov. 2022 Aug 5;12(8):1828. doi: 10.1158/2159-8290.CD-NB2022-0043.
3
Trastuzumab deruxtecan for HER2+ advanced breast cancer.曲妥珠单抗-德曲妥珠单抗用于治疗 HER2 阳性晚期乳腺癌。
Future Oncol. 2022 Jan;18(1):7-19. doi: 10.2217/fon-2021-0550. Epub 2021 Nov 26.
4
Exploring DESTINY: the Past, Present, and Future of Trastuzumab Deruxtecan.探索DESTINY：德曲妥珠单抗的过去、现在与未来
Curr Oncol Rep. 2024 Jan;26(1):1-9. doi: 10.1007/s11912-023-01478-2. Epub 2023 Dec 13.
5
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.曲妥珠单抗-德鲁替康与曲妥珠单抗-美坦新用于乳腺癌。
N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022.
6
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.曲妥珠单抗-德鲁替康（DS-8201a）治疗既往接受过曲妥珠单抗-美坦新偶联物治疗的晚期 HER2 阳性乳腺癌患者：一项剂量扩展、I 期研究。
Lancet Oncol. 2019 Jun;20(6):816-826. doi: 10.1016/S1470-2045(19)30097-X. Epub 2019 Apr 29.
7
Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).曲妥珠单抗衍生药物德曲妥珠单抗（DS-8201a）和（Vic-）曲妥珠单抗杜卡鲁单抗（SYD985）：新型抗 HER2 抗体药物偶联物在乳腺癌中的应用，超越 T-DM1
Eur J Med Chem. 2019 Dec 1;183:111682. doi: 10.1016/j.ejmech.2019.111682. Epub 2019 Sep 6.
8
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.恩美曲妥珠单抗治疗既往 HER2 阳性乳腺癌。
N Engl J Med. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510. Epub 2019 Dec 11.
9
HER2-Targeted Therapy Shows Promise across Tumor Types.曲妥珠单抗靶向治疗在多种肿瘤类型中显示出疗效。
Cancer Discov. 2023 Aug 4;13(8):OF3. doi: 10.1158/2159-8290.CD-NB2023-0047.
10
[New approval: Trastuzumab-deruxtecan for metastatic breast cancer HER2].[新批准：曲妥珠单抗-德曲妥珠单抗用于转移性乳腺癌HER2]
Bull Cancer. 2021 Sep;108(9):783-784. doi: 10.1016/j.bulcan.2021.05.001. Epub 2021 Jun 16.
引用本文的文献
1
Prevalence and Clinical Outcomes of Human Epidermal Growth Factor Receptor 2 Expression in Patients With Advanced Urothelial Carcinoma.晚期尿路上皮癌患者中人表皮生长因子受体2表达的患病率及临床结局
World J Oncol. 2025 Feb;16(1):51-58. doi: 10.14740/wjon1966. Epub 2024 Dec 31.
2
Combination Therapy of Pyrotinib and Metronomic Vinorelbine in HER2+ Advanced Breast Cancer after Trastuzumab Failure (PROVE): A Prospective Phase 2 Study.吡咯替尼与节拍性长春瑞滨联合治疗曲妥珠单抗治疗失败后的HER2+晚期乳腺癌（PROVE）：一项前瞻性2期研究。
Cancer Res Treat. 2025 Apr;57(2):434-442. doi: 10.4143/crt.2024.340. Epub 2024 Aug 9.
3
New-generation technologies for spatial tissue analysis, indispensable tools for deciphering intratumor heterogeneity in the development of antibody-drug conjugates and radio-immunoconjugates for cancer treatment.新一代空间组织分析技术，是在开发用于癌症治疗的抗体药物偶联物和放射免疫偶联物过程中破译肿瘤内异质性的不可或缺的工具。
Transl Breast Cancer Res. 2023 Sep 20;4:28. doi: 10.21037/tbcr-23-38. eCollection 2023.
4
Inetetamab combined with pyrotinib and oral vinorelbine for patients with human epidermal growth factor receptor 2 positive advanced breast cancer: A single-arm phase 2 clinical trial.因他妥单抗联合吡咯替尼及口服长春瑞滨治疗人表皮生长因子受体2阳性晚期乳腺癌患者：一项单臂2期临床试验。
Cancer Pathog Ther. 2023 Oct 30;2(1):31-37. doi: 10.1016/j.cpt.2023.10.004. eCollection 2024 Jan.
5
Emerging Targets for Systemic Treatment of Gastric Cancer: HER2 and Beyond.胃癌全身治疗的新兴靶点：HER2及其他
J Gastric Cancer. 2024 Jan;24(1):29-56. doi: 10.5230/jgc.2024.24.e6.
6
Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer.HER2阳性乳腺癌中的肿瘤浸润淋巴细胞与免疫反应
Cancers (Basel). 2022 Dec 8;14(24):6034. doi: 10.3390/cancers14246034.
本文引用的文献
1
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.曲妥珠单抗-德鲁替康与曲妥珠单抗-美坦新用于乳腺癌。
N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022.
2
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.曲妥珠单抗-德鲁替康在 HER2 低表达晚期乳腺癌患者中的抗肿瘤活性和安全性：来自一项 Ib 期研究的结果。
J Clin Oncol. 2020 Jun 10;38(17):1887-1896. doi: 10.1200/JCO.19.02318. Epub 2020 Feb 14.
3
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.恩美曲妥珠单抗治疗既往 HER2 阳性乳腺癌。
N Engl J Med. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510. Epub 2019 Dec 11.
4
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.曲妥珠单抗-德鲁替康（DS-8201a）治疗既往接受过曲妥珠单抗-美坦新偶联物治疗的晚期 HER2 阳性乳腺癌患者：一项剂量扩展、I 期研究。
Lancet Oncol. 2019 Jun;20(6):816-826. doi: 10.1016/S1470-2045(19)30097-X. Epub 2019 Apr 29.
5
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.曲妥珠单抗联合辅助化疗用于人表皮生长因子受体2阳性乳腺癌：NSABP B-31和NCCTG N9831总生存的计划联合分析
J Clin Oncol. 2014 Nov 20;32(33):3744-52. doi: 10.1200/JCO.2014.55.5730. Epub 2014 Oct 20.
6
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.对于过度表达HER2的转移性乳腺癌，使用化疗加一种抗HER2单克隆抗体进行治疗。
N Engl J Med. 2001 Mar 15;344(11):783-92. doi: 10.1056/NEJM200103153441101.
7
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.人类乳腺癌：HER-2/neu癌基因扩增与复发及生存的相关性。
Science. 1987 Jan 9;235(4785):177-82. doi: 10.1126/science.3798106.
Zotero 插件